相似文献
1
Design of a MUC1-based tricomponent vaccine adjuvanted with FSL-1 for cancer immunotherapy.
Medchemcomm. 2019 Jul 12;10(12):2073-2077. doi: 10.1039/c9md00254e. eCollection 2019 Dec 1.
2
Design, Synthesis, and Preliminary Immunological Studies of MUC1-Based Antitumor Vaccines Adjuvanted with - and -FSL-1.
ACS Med Chem Lett. 2020 Jun 22;11(7):1371-1376. doi: 10.1021/acsmedchemlett.9b00579. eCollection 2020 Jul 9.
3
Synthetic self-adjuvanted multivalent Mucin 1 (MUC1) glycopeptide vaccines with improved in vivo antitumor efficacy.
MedComm (2020). 2024 Feb 9;5(2):e484. doi: 10.1002/mco2.484. eCollection 2024 Feb.
4
Aberrant Glycosylation of Anchor-Optimized MUC1 Peptides Can Enhance Antigen Binding Affinity and Reverse Tolerance to Cytotoxic T Lymphocytes.
Biomolecules. 2016 Jun 29;6(3):31. doi: 10.3390/biom6030031.
5
Synthetic and immunological studies on trimeric MUC1 immunodominant motif antigen-based anti-cancer vaccine candidates.
Org Biomol Chem. 2018 Feb 7;16(6):993-999. doi: 10.1039/c7ob02976d.
6
Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
J Immunother. 2003 Jan-Feb;26(1):47-62. doi: 10.1097/00002371-200301000-00006.
7
Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.
ChemMedChem. 2017 May 22;12(10):722-727. doi: 10.1002/cmdc.201700254. Epub 2017 May 5.
8
Synthetic MUC1 Antitumor Vaccine Candidates with Varied Glycosylation Pattern Bearing R/S-configured Pam3 CysSerLys4.
Chembiochem. 2016 Aug 3;17(15):1412-5. doi: 10.1002/cbic.201600206. Epub 2016 Jun 15.
9
Synthesis and biological evaluation of a novel MUC1 glycopeptide conjugate vaccine candidate comprising a 4'-deoxy-4'-fluoro-Thomsen-Friedenreich epitope.
Beilstein J Org Chem. 2015 Jan 23;11:155-161. doi: 10.3762/bjoc.11.15. eCollection 2015.
10
Liposomal Antitumor Vaccines Targeting Mucin 1 Elicit a Lipid-Dependent Immunodominant Response.
Chem Asian J. 2019 Jun 14;14(12):2116-2121. doi: 10.1002/asia.201900448. Epub 2019 May 21.
引用本文的文献
1
The Oncoprotein Mucin 1 in Pancreatic Cancer Onset and Progression: Potential Clinical Implications.
Biomolecules. 2025 Feb 13;15(2):275. doi: 10.3390/biom15020275.
2
Diphtheria Toxoid-Derived T-Helper Epitope and α-galactosylceramide Synergistically Enhance the Immunogenicity of Glycopeptide Antigen.
ACS Pharmacol Transl Sci. 2024 Nov 4;7(12):3889-3901. doi: 10.1021/acsptsci.4c00437. eCollection 2024 Dec 13.
3
Development of Methamphetamine Conjugated Vaccine through Hapten Design: In Vitro and In Vivo Characterization.
Vaccines (Basel). 2023 Feb 2;11(2):340. doi: 10.3390/vaccines11020340.
4
Synthesis and functional studies of self-adjuvanting multicomponent anti-HER2 cancer vaccines.
RSC Adv. 2021 Oct 15;11(53):33814-33822. doi: 10.1039/d1ra06146a. eCollection 2021 Oct 8.
5
Pancreatic cancer and adaptive metabolism in a nutrient-deficient environment.
Cent Eur J Immunol. 2021;46(3):388-394. doi: 10.5114/ceji.2021.109693. Epub 2021 Oct 6.
6
Mucins as anti-cancer targets: perspectives of the glycobiologist.
Glycoconj J. 2021 Aug;38(4):459-474. doi: 10.1007/s10719-021-09986-8. Epub 2021 Mar 11.
7
Mucins in pancreatic cancer: A well-established but promising family for diagnosis, prognosis and therapy.
J Cell Mol Med. 2020 Sep;24(18):10279-10289. doi: 10.1111/jcmm.15684. Epub 2020 Aug 3.
8
Tumor-associated O-glycans of MUC1: Carriers of the glyco-code and targets for cancer vaccine design.
Semin Immunol. 2020 Feb;47:101389. doi: 10.1016/j.smim.2020.101389. Epub 2020 Jan 9.
9
Going Native: Synthesis of Glycoproteins and Glycopeptides via Native Linkages To Study Glycan-Specific Roles in the Immune System.
Bioconjug Chem. 2019 Nov 20;30(11):2715-2726. doi: 10.1021/acs.bioconjchem.9b00588. Epub 2019 Oct 18.
本文引用的文献
1
Reduced Breast Tumor Growth after Immunization with a Tumor-Restricted MUC1 Glycopeptide Conjugated to Tetanus Toxoid.
Cancer Immunol Res. 2019 Jan;7(1):113-122. doi: 10.1158/2326-6066.CIR-18-0256. Epub 2018 Nov 9.
2
Protective Epitope Discovery and Design of MUC1-based Vaccine for Effective Tumor Protections in Immunotolerant Mice.
J Am Chem Soc. 2018 Dec 5;140(48):16596-16609. doi: 10.1021/jacs.8b08473. Epub 2018 Nov 19.
3
Synthesis of a Self-Adjuvanting MUC1 Vaccine via Diselenide-Selenoester Ligation-Deselenization.
ACS Chem Biol. 2018 Dec 21;13(12):3279-3285. doi: 10.1021/acschembio.8b00675. Epub 2018 Nov 14.
4
Antitumor Humoral and T Cell Responses by Mucin-1 Conjugates of Bacteriophage Qβ in Wild-type Mice.
ACS Chem Biol. 2018 Jun 15;13(6):1668-1676. doi: 10.1021/acschembio.8b00313. Epub 2018 May 30.
5
Syntheses and Immunological Evaluation of Self-Adjuvanting Clustered N-Acetyl and N-Propionyl Sialyl-Tn Combined with a T-helper Cell Epitope as Antitumor Vaccine Candidates.
Angew Chem Int Ed Engl. 2018 Jul 2;57(27):8219-8224. doi: 10.1002/anie.201804437. Epub 2018 Jun 7.
6
Synthesis, Liposomal Formulation, and Immunological Evaluation of a Minimalistic Carbohydrate-α-GalCer Vaccine Candidate.
J Med Chem. 2018 Jun 14;61(11):4918-4927. doi: 10.1021/acs.jmedchem.8b00312. Epub 2018 May 18.
7
Designable Immune Therapeutical Vaccine System Based on DNA Supramolecular Hydrogels.
ACS Appl Mater Interfaces. 2018 Mar 21;10(11):9310-9314. doi: 10.1021/acsami.8b00312. Epub 2018 Mar 12.
8
Synthesis and Immunological Evaluation of a Multicomponent Cancer Vaccine Candidate Containing a Long MUC1 Glycopeptide.
Chembiochem. 2018 Jan 18;19(2):121-125. doi: 10.1002/cbic.201700424. Epub 2017 Nov 30.
9
Elements of cancer immunity and the cancer-immune set point.
Nature. 2017 Jan 18;541(7637):321-330. doi: 10.1038/nature21349.
10
Fully synthetic self-adjuvanting MUC1-fibroblast stimulating lipopeptide 1 conjugates as potential cancer vaccines.
Chem Commun (Camb). 2016 Sep 18;52(72):10886-9. doi: 10.1039/c6cc04623a. Epub 2016 Aug 17.
Zotero 插件